BioRestorative Therapies (BRTX) Other Non Operating Income (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Other Non Operating Income came in at $568966.0 in Q4 2025, down 42.43% YoY from $988316.0 in Q4 2024, and up 61079.14% on a QoQ basis from $930.0 in Q3 2025.
BioRestorative Therapies (BRTX) Other Non Operating Income (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 14 years of Other Non Operating Income data on file, last reported at $568966.0 in Q4 2025.
- Quarterly Other Non Operating Income fell 42.43% year-over-year to $568966.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$63705.0 (down 107.47% YoY) and the FY2025 annual result came in at $1.1 million, up 643.46% from the prior year.
- Other Non Operating Income rose to $568966.0 in Q4 2025, from $930.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $7.7 million in Q3 2023 to a low of -$7.8 million in Q2 2022.
- A 4-year average of $784589.9 and a median of $58236.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 873.0% — and 2025, when it tumbled 361.79%.
- Tracing BRTX's Other Non Operating Income over 4 years: stood at $3.7 million in 2022, then climbed by 3.97% to $3.8 million in 2023, then slumped by 74.31% to $988316.0 in 2024, then tumbled by 42.43% to $568966.0 in 2025.
- The last three Other Non Operating Income figures came in at $568966.0 (Q4 2025), $930.0 (Q3 2025), and $518.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 568,966.00 |
| Sep 30, 2025 | 930.00 |
| Jun 30, 2025 | 518.00 |
| Mar 31, 2025 | -634,119.00 |
| Dec 31, 2024 | 988,316.00 |
| Sep 30, 2024 | 566.00 |
| Jun 30, 2024 | 911.00 |
| Mar 31, 2024 | -137,319.00 |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | 7.69 Mn |
| Jun 30, 2023 | 39,812.00 |
| Mar 31, 2023 | 76,660.00 |
| Dec 31, 2022 | 3.70 Mn |
| Sep 30, 2022 | 790,723.00 |
| Jun 30, 2022 | -7.78 Mn |
| Mar 31, 2022 | 3.39 Mn |
| Dec 31, 2020 | 1.48 Mn |
| Jun 30, 2020 | -2.80 Mn |
| Mar 31, 2020 | 658,152.00 |
| Dec 31, 2019 | 4.19 Mn |